Clinical laboratory billing sits at the intersection of strict CMS fee schedule rules, CLIA compliance, payer-specific LCDs, and rapidly evolving molecular code sets—where a missing modifier or incorrect panel code can trigger automatic denial or post-payment audit. VeriMedix brings specialized lab billing expertise to maximize clean-claim rates and defend revenue across chemistry, hematology, urinalysis, and molecular testing.
Clinical laboratory billing is governed by the CMS Clinical Laboratory Fee Schedule (CLFS), which sets payment rates for tests paid under Part B, and by Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs) that establish medical necessity and frequency requirements for high-volume tests. Accurate billing requires correct selection between panel codes (which bundle specific analytes) and individual analyte codes. A panel code such as 80053 (Comprehensive Metabolic Panel, CMP) can only be billed when all required components are performed and reported together on the same date of service. If any component is missing, individual analyte codes must be billed instead—billing the panel code for incomplete testing is overcoding subject to recoupment. Similarly, the basic metabolic panel (80048), lipid panel (80061), hepatic function panel (80076), and thyroid panel (80091) each have defined component requirements that must be verified before panel code submission.
CLIA certification is the regulatory backbone of laboratory billing. Every laboratory must hold a current, valid CLIA certificate appropriate to the complexity level of each test performed. For CLIA-waived tests—those approved by the FDA for simple, low-risk testing using specified kit-based methods—the modifier QW is generally required to be appended to the HCPCS or CPT code when billed to Medicare and many commercial payers. Failure to include QW where required results in automatic rejection. Notable exceptions are codes 81002, 81025, 82270, 82272, 82962, 83026, 84830, 85013, and 85651, which do not require QW even when performed with a waived test kit. CMS periodically updates the list of FDA-approved waived tests and their corresponding HCPCS/QW codes.
Molecular and genomic testing creates the most complex billing scenarios in clinical laboratories. Tier 1 molecular pathology codes (81162–81383) are gene-specific and must be used when a code exists for the specific analyte tested. Tier 2 codes (81400–81408) require the specific analyte to be identified in the narrative field of the claim. Proprietary Laboratory Analyses (PLA) codes—updated quarterly—apply to single-source assays and take precedence over generic molecular codes. Next-generation sequencing panels under the MolDX program require pre-approval for Medicare coverage. Stacking individual codes when a panel code exists (e.g., billing individual genes instead of 81445 for a 5–50 gene solid tumor panel) is a recognized coding error subject to CMS enforcement. ABNs and payer-specific LCDs govern frequency limits for common tests such as HbA1c, vitamin D, PSA, and lipid panels.
Below are commonly billed codes our certified coders manage for clinical laboratory practices. Always confirm payer-specific coverage and current code values.
| Code | Description | Billing note |
|---|---|---|
80048 | Basic metabolic panel (BMP): calcium, CO2, chloride, creatinine, glucose, potassium, sodium, BUN | All 8 components must be performed and reported; bill individual codes if any component is omitted |
80053 | Comprehensive metabolic panel (CMP): all BMP components plus albumin, bilirubin total, ALT, AST, alkaline phosphatase, total protein | 14 specified components required; do not bill 80053 + BMP on same DOS—included in CMP |
80061 | Lipid panel: total cholesterol, HDL cholesterol, triglycerides, LDL (direct or calculated) | All 4 components required; frequency limits vary by payer (typically once every 5 years for Medicare without qualifying diagnosis) |
85025 | Complete blood count (CBC) with automated differential WBC count | Most common hematology code; do not also bill 85007 differential count—bundled per NCCI |
83036 | Hemoglobin A1c (HbA1c) | Medicare frequency limit generally 2–4 per year based on diabetes control status; QW modifier when performed with waived device (e.g., 83036QW) |
82306 | Vitamin D, 25-hydroxy (calcidiol) | Subject to strict LCD coverage criteria; must document qualifying diagnosis (e.g., osteoporosis, malabsorption); frequency limits apply |
87880 | Infectious agent antigen detection, direct optical observation; streptococcus A | CLIA-waived when performed with approved kit; append QW (87880QW); one of highest-volume waived tests |
81003 | Urinalysis, automated, without microscopy | Do not bill with 81002 (manual) or 81001 (with microscopy) for the same specimen on the same date—bill the method actually used |
81445 | Targeted genomic sequence analysis panel, solid organ neoplasm, 5–50 genes | Requires MolDX program approval for Medicare; document tumor type and panel composition; do not stack individual gene codes |
Our standard operating procedures for clinical laboratory revenue cycle management — the step-by-step workflow we follow on every claim:
These are the issues we see most often in clinical laboratory billing — and exactly how we resolve them:
Billing 80053 (CMP) when not all 14 required components were resulted, or 80048 (BMP) when a component was not tested, is overcoding that survives front-end edits but triggers recoupment on audit. Fix: implement a lab information system (LIS) rule that maps panel codes to component completion status before releasing charges; automatically downcode to individual analytes if the panel definition is not met.
Tests such as 87880 (rapid strep), 87804 (rapid flu), and 83036 when performed with a waived device require QW to be recognized by Medicare as a waived test claim. Missing QW causes automatic rejection. Fix: build a billing system rule that appends QW to all codes on the approved waived-test list when the performing facility holds a Certificate of Waiver; update the list each time CMS publishes a new waived-test change request.
Modifier 91 is valid only for clinically indicated repeat testing—not for tests repeated because of instrument errors, sample dilution, or QC failures. Auditors will request documentation and deny claims where modifier 91 lacks clinical support. Fix: require an order from the treating provider with a clinical rationale before modifier 91 is applied; prohibit billing staff from applying 91 based solely on the lab's internal repeat log.
Billing individual Tier 1 or Tier 2 gene codes when a 5–50 gene panel should be reported as 81445 (solid tumor) or 81450 (hematologic) constitutes unbundling per CMS guidance. This inflates reimbursement and is a documented enforcement target. Fix: implement a pre-billing check that flags claims with 5 or more molecular codes from the same specimen on the same date and reviews whether a panel code (or MolDX-approved assay) should be substituted.
Payer LCDs set frequency limits on tests like HbA1c, vitamin D (82306), and PSA (84153). Testing beyond these limits without a qualifying diagnosis triggers automatic denial. Fix: integrate payer-specific frequency rules into the ordering workflow; generate an ABN and obtain patient signature before performing a test that would exceed the covered frequency; document the clinical justification in the order if an exception applies.
Verimedix works inside the systems clinical laboratory practices already use, including:
The CLFS is the CMS payment schedule for clinical laboratory tests paid under Medicare Part B. It sets rates for hundreds of tests based on reported market rates from high-volume labs (private-payor rate reporting). Medicare pays 80% of the CLFS rate after any applicable co-insurance; labs that participate in Medicare accept the CLFS amount as payment in full and cannot balance-bill patients for the 20%. The CLFS is updated periodically based on private-payor market data under the Protecting Access to Medicare Act (PAMA) methodology.
An Advance Beneficiary Notice of Non-Coverage (ABN) is required when a lab has reason to believe Medicare may deny a specific service as not medically necessary for a specific patient. The ABN must identify the specific test(s), the reason the lab believes it may not be covered, and the estimated cost. Generic blanket ABNs are not acceptable for Medicare. A properly executed ABN shifts financial responsibility to the patient and allows billing with modifier GA (ABN on file).
Yes. A physician who owns laboratory equipment and performs testing in their office (POL) bills the global fee for both components without a modifier. The global fee includes the technical work (running the test) and any physician interpretation included in that code's definition. A POL may not separately bill modifier 26 on top of the global code, as that would represent double-billing for the professional component.
A Certificate of Waiver allows a laboratory to perform only FDA-approved waived tests (the simplest, lowest-risk tests). A Certificate of Compliance allows moderate-complexity or high-complexity testing and requires regular inspections by the state or an approved accrediting organization. Billing a high-complexity test (e.g., most molecular tests, most hematology tests) from a facility with only a Certificate of Waiver will result in claim denial because CMS validates CLIA certificate level against the test's CLIA complexity category.
PLA (Proprietary Laboratory Analyses) codes are updated quarterly by the AMA. New codes take effect on January 1, April 1, July 1, and October 1 of each year. Labs billing proprietary molecular assays must review PLA code updates each quarter and update their billing system code tables before the effective date. Using an outdated or generic molecular code when a specific PLA code exists risks denials and audit exposure.
For molecular and genomic tests, the billing laboratory must have on file: (1) the signed physician requisition with the ordering provider's NPI, ICD-10 diagnosis code(s), and clinical indication; (2) for Tier 2 or unlisted codes, the specific gene or analyte identified in the narrative; (3) for tests requiring MolDX approval, the current technical assessment approval documentation; and (4) for hereditary or BRCA testing, signed patient informed consent. Without this documentation, claims are subject to denial on audit.
Yes. Medicare Part B covers laboratory tests ordered by physicians and by certain non-physician practitioners (NPPs) authorized under state law to order laboratory tests, including nurse practitioners, physician assistants, certified nurse midwives, and clinical nurse specialists. The ordering provider's NPI must be correctly recorded on the claim. Tests ordered by providers who are not enrolled in Medicare will not be covered.
Verimedix handles the entire clinical laboratory revenue cycle — coding, submission, denials, and A/R — so your team can focus on patients.